Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Tamura T, Ninomiya K, Kubo T, Kuyama S, Tachibana S, Inoue K, Chikamori K, Kudo K, Ochi N, Harada D, Maeda Y, Kiura K. Tamura T, et al. Among authors: kuyama s. Thorac Cancer. 2022 Feb;13(3):453-459. doi: 10.1111/1759-7714.14281. Epub 2021 Dec 28. Thorac Cancer. 2022. PMID: 34964270 Free PMC article.
A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer.
Shibayama T, Hotta K, Takigawa N, Tada A, Ueoka H, Harita S, Kiura K, Tabata M, Segawa Y, Nogami N, Kuyama S, Shinkai T, Tanimoto M. Shibayama T, et al. Among authors: kuyama s. Lung Cancer. 2006 Aug;53(2):189-95. doi: 10.1016/j.lungcan.2006.05.008. Epub 2006 Jun 27. Lung Cancer. 2006. PMID: 16806573 Clinical Trial.
A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M, Kiura K, Okimoto N, Segawa Y, Shinkai T, Yonei T, Kuyama S, Harita S, Hotta K, Ueoka H, Tanimoto M. Tabata M, et al. Among authors: kuyama s. Cancer Chemother Pharmacol. 2007 Jun;60(1):1-6. doi: 10.1007/s00280-006-0336-0. Epub 2007 Mar 29. Cancer Chemother Pharmacol. 2007. PMID: 17393168 Clinical Trial.
Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M; Okayama Lung Cancer Study Group. Kiura K, et al. Among authors: kuyama s. J Thorac Oncol. 2007 Jan;2(1):44-50. doi: 10.1097/JTO.0b013e31802bafe2. J Thorac Oncol. 2007. PMID: 17410009 Free article. Clinical Trial.
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
Hotta K, Kiura K, Takigawa N, Kuyama S, Segawa Y, Yonei T, Gemba K, Aoe K, Shibayama T, Matsuo K, Kamei H, Fujiwara Y, Bessho A, Moritaka T, Sugimoto K, Tabata M, Ueoka H, Tanimoto M. Hotta K, et al. Among authors: kuyama s. J Cancer Res Clin Oncol. 2009 Jan;135(1):117-23. doi: 10.1007/s00432-008-0431-1. Epub 2008 Jul 11. J Cancer Res Clin Oncol. 2009. PMID: 18618142
A phase I study of combination S-1 plus cisplatin chemotherapy with concurrent thoracic radiation for locally advanced non-small cell lung cancer.
Chikamori K, Kishino D, Takigawa N, Hotta K, Nogami N, Kamei H, Kuyama S, Gemba K, Takemoto M, Kanazawa S, Ueoka H, Segawa Y, Takata S, Tabata M, Kiura K, Tanimoto M; Okayama Lung Cancer Study Group. Chikamori K, et al. Among authors: kuyama s. Lung Cancer. 2009 Jul;65(1):74-9. doi: 10.1016/j.lungcan.2008.10.019. Epub 2008 Dec 3. Lung Cancer. 2009. PMID: 19056143 Clinical Trial.
95 results